NCT01069263

Brief Summary

The purpose of this study is to compare the efficacy of hyperbaric oxygen therapy (HBOT) to intravesical Dimethyl Sulfoxide (DMSO) instillation for the treatment of patients who suffers from Interstitial Cystitis / Painful bladder syndrome.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 10, 2010

Completed
22 days until next milestone

Study Start

First participant enrolled

February 1, 2010

Completed
16 days until next milestone

First Posted

Study publicly available on registry

February 17, 2010

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
Last Updated

April 5, 2011

Status Verified

February 1, 2010

Enrollment Period

5.1 years

First QC Date

January 10, 2010

Last Update Submit

April 4, 2011

Conditions

Keywords

Interstitial cystitisPainful bladder syndromeChronic pelvic painDMSOHyperbaric oxygen therapy

Outcome Measures

Primary Outcomes (1)

  • Subjective improvement will be assessed by several questionnaires: the Oleary Sant symptom index score, bladder diary, 1-10 visual analogue scale for pain, PSQ4 questionnaire

    1-4 weeks post treatment

Secondary Outcomes (1)

  • Objective improvement will be assessed by urodynamic test. The following parameters will be addressed: cystometric capacity, 1st sensation, normal sensation

    1-4 weeks post treatment

Study Arms (2)

Intravesical DMSO instillation

ACTIVE COMPARATOR

50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.

Drug: DMSO

Hyperbaric Oxygen Therapy (HBOT)

EXPERIMENTAL

Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.

Other: Hyperbaric Oxygen Therapy

Interventions

60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.

Also known as: HBOT, Hyperbaric chamber, Hyperbaric therapy
Hyperbaric Oxygen Therapy (HBOT)
DMSODRUG

50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.

Also known as: dimethyl sulfoxide
Intravesical DMSO instillation

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • NIDDK diagnosis of interstitial cystitis

You may not qualify if:

  • Previous treatment of hyperbaric therapy
  • Contraindication for hyperbaric therapy (mid-ear pathology, abnormal chest X-ray, Claustrophobia, pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assaf Harofe Medical Center

Zeriffin, 70300, Israel

RECRUITING

Related Publications (2)

  • Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988 Jul;140(1):36-9. doi: 10.1016/s0022-5347(17)41478-9.

    PMID: 3288775BACKGROUND
  • van Ophoven A, Rossbach G, Oberpenning F, Hertle L. Hyperbaric oxygen for the treatment of interstitial cystitis: long-term results of a prospective pilot study. Eur Urol. 2004 Jul;46(1):108-13. doi: 10.1016/j.eururo.2004.03.002.

Related Links

MeSH Terms

Conditions

Cystitis, Interstitial

Interventions

Hyperbaric OxygenationDimethyl Sulfoxide

Condition Hierarchy (Ancestors)

CystitisUrinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Oxygen Inhalation TherapyRespiratory TherapyTherapeuticsSulfoxidesSulfur CompoundsOrganic Chemicals

Study Officials

  • Kobi Stav, MD

    Assaf Harofe Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

January 10, 2010

First Posted

February 17, 2010

Study Start

February 1, 2010

Primary Completion

March 1, 2015

Study Completion

July 1, 2015

Last Updated

April 5, 2011

Record last verified: 2010-02

Locations